Temporal trends of COVID-19 related in-hospital mortality and demographics in Switzerland - a retrospective single centre cohort study.


Journal

Swiss medical weekly
ISSN: 1424-3997
Titre abrégé: Swiss Med Wkly
Pays: Switzerland
ID NLM: 100970884

Informations de publication

Date de publication:
19 07 2021
Historique:
entrez: 29 7 2021
pubmed: 30 7 2021
medline: 10 8 2021
Statut: epublish

Résumé

The aim of this study was to analyse the demographics, risk factors and in-hospital mortality rates of patients admitted with coronavirus disease 2019 (COVID-19) to a tertiary care hospital in Switzerland. In this single-centre retrospective cohort study at the University Hospital Basel, we included all patients with confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection hospitalised from 27 February 2020 to 10 May 2021. Patients’ characteristics were extracted from the electronic medical record system. The primary outcome of this study was temporal trends of COVID-19-related in-hospital mortality. Secondary outcomes were COVID-19-related mortality in patients hospitalised on the intensive care unit (ICU), admission to ICU, renal replacement therapy and length of hospital stay, as well as a descriptive analysis of risk factors for in-hospital mortality. During the study period we included 943 hospitalisations of 930 patients. The median age was 65 years (interquartile range [IQR] 53–76) and 63% were men. The numbers of elderly patients, patients with multiple comorbidities and need for renal replacement therapy decreased from the first and second to the third wave. The median length of stay and need for ICU admission were similar in all waves. Throughout the study period 88 patients (9.3%) died during the hospital stay. Crude in-hospital mortality was similar over the course of the first two waves (9.5% and 10.2%, respectively), whereas it decreased in the third wave (5.4%). Overall mortality in patients without comorbidities was low at 1.6%, but it increased in patients with any comorbidity to 12.6%. Predictors of all-cause mortality over the whole period were age (adjusted odds ratio [aOR] per 10-year increase 1.81, 95% confidence interval [CI] 1.45–2.26; p <0.001), male sex (aOR 1.68, 95% CI 1.00–2.82; p = 0.048), immunocompromising condition (aOR 2.09, 95% CI 1.01–4.33; p = 0.048) and chronic kidney disease (aOR 2.25, 95% CI 1.35–3.76; p = 0.002). In our study in-hospital mortality was 9.5%, 10.2% and 5.4% in the first, second and third waves, respectively. Age, immunocompromising condition, male sex and chronic kidney disease were factors associated with in-hospital mortality. Importantly, patients without any comorbidity had a very low in-hospital mortality regardless of age.

Identifiants

pubmed: 34324697
doi: 10.4414/smw.2021.20572
pii: Swiss Med Wkly. 2021;151:w20572
doi:
pii:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

w20572

Auteurs

Matthias Diebold (M)

Clinic for Transplantation Immunology and Nephrology, University Hospital Basel, Switzerland.

Aurélien Emmanuel Martinez (AE)

Division of infectious Diseases and Hospital Epidemiology, University Hospital Basel, Switzerland.

Kai-Manuel Adam (KM)

Division of infectious Diseases and Hospital Epidemiology, University Hospital Basel, Switzerland.

Stefano Bassetti (S)

Division of Internal Medicine, University Hospital Basel, Switzerland.

Michael Osthoff (M)

Division of Internal Medicine, University Hospital Basel, Switzerland / Department of Clinical Research, University of Basel, Switzerland.

Elianne Kassi (E)

Division of Internal Medicine, University Hospital Basel, Switzerland.

Jürg Steiger (J)

Clinic for Transplantation Immunology and Nephrology, University Hospital Basel, Switzerland.

Hans Pargger (H)

Intensive Care Unit, University Basel, University Hospital, Switzerland.

Martin Siegemund (M)

Department of Clinical Research, University of Basel, Switzerland / Intensive Care Unit, University Basel, University Hospital, Switzerland.

Manuel Battegay (M)

Division of infectious Diseases and Hospital Epidemiology, University Hospital Basel, Switzerland.

Nina Khanna (N)

Division of infectious Diseases and Hospital Epidemiology, University Hospital Basel, Switzerland.

Stefan Schaub (S)

Clinic for Transplantation Immunology and Nephrology, University Hospital Basel, Switzerland.

Conrad Wesch (C)

Intensive Care Unit, University Basel, University Hospital, Switzerland.

Michael Dickenmann (M)

Clinic for Transplantation Immunology and Nephrology, University Hospital Basel, Switzerland.

Maja Weisser (M)

Division of infectious Diseases and Hospital Epidemiology, University Hospital Basel, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH